SDI Review Form 1.6

Journal Name:	**Journal of Cancer and Tumor International**
Manuscript Number:	**Ms_JCTI_48202**
Title of the Manuscript:	**Diagnostic significance of Beclin-1 and Transforming growth factor β (TGF-β) in Breast Cancer**
Type of the Article	**Original Research Papers**

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty'**, provided the manuscript is scientifically robust and technically sound.
To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline)

PART 1: Review Comments

	Reviewer's comment	Author's comment *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)*
Compulsory REVISION comments	**There is considerable revision that needs to be done here.** 1. The writing, grammar, and formatting (of both text and figures) requires extensive editing. It is full of errors, poorly expressed ideas, punctuation and capitalization errors, poorly made figures and tables (see Table 2, upper right box), etc. 2. The Results section needs fleshing out with additional text – right now it is just a few sentences with figures and tables one after the other. Some more explanation of what is going in is necessary. 3. Another comment concerns the RT-PCR. Is there any data that demonstrate whether the RNA used is DNA free? Therefore, is there any negative control, such as doing the RT-PCR but skipping the RT step? If the RNA is really DNA free, then performing PCR directly on the RNA should not yield a band. Can the authors comment on this, at least? If they have any of these RNA samples left over, showing that no product is formed without the RT step would be helpful. Or do you use primers that span exon/intron junctions and thus can distinguish DNA from fully processed RNA? 4. Can you specify in more detail what data were evaluated with parametric and which with non-parametric statistics and the justification? 5. The Discussion is somewhat disorganized. Some more explanation as to why BECN1 is considered a tumor suppressor yet is associated here with worse outcomes would be helpful.	
Minor REVISION comments		
Optional/General comments		

SDI Review Form 1.6

	Reviewer's comment	Author's comment *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)*
Are there ethical issues in this manuscript?	*(If yes, Kindly please write down the ethical issues here in details)*	

Reviewer Details:

Name:	*Michael Bordonaro*
Department, University & Country	*GCSOM, USA*